Summit Therapeutics Raises $2.0 Billion in Convertible Preferred Private Placement With AstraZeneca

Summit Therapeutics announced a $2.0 billion private placement through a securities purchase agreement with AstraZeneca for Class A Convertible Preferred Stock. The deal covers 108,955.3686 preferred shares at $18,356.14 per share, each convertible into 1,000 common shares (implying $18.3561 per co…